{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T08:45:01Z","timestamp":1776761101488,"version":"3.51.2"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>With cardiac myosin inhibitors emerging as a novel pharmacological option instead of septal reduction therapies (SRT) in obstructive hypertrophic cardiomyopathy (HCM), contemporary data on national long-term outcomes after SRT are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In this nationwide cohort study from 2015 to 2021, patients with obstructive HCM undergoing SRT (surgical myectomy or transcoronary ablation of septal hypertrophy) were 1:8 propensity score-matched with non-obstructive HCM patients or surgical controls undergoing appendectomy without heart disease in recent records. As assessed in time-to-event analyses, the primary outcome was a composite of all-cause mortality after discharge and rehospitalization for heart failure. After matching, 125 patients with obstructive HCM hospitalized for SRT were compared to 743 patients hospitalized with non-obstructive HCM. The incidence rate (IR) of the primary outcome was lower in the SRT group {12.62 vs. 74.86 per 1000 patient-years (py); hazard ratio (HR), 0.17 [95% confidence interval (CI), 0.07\u20130.42]; median follow-up 31 months}. In the second comparison, 126 patients with obstructive HCM undergoing SRT were matched to 560 surgical controls without heart disease undergoing laparoscopic appendectomy. The IR of the primary outcome after SRT was comparable to that of surgical controls without heart disease [12.61 vs. 8.09 per 1000 py; HR, 1.53 (95% CI, 0.56\u20134.18); median follow-up 41 months].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this nationwide cohort study, SRT was associated with a lower incidence of all-cause mortality after discharge and rehospitalization for heart failure compared to patients hospitalized with non-obstructive HCM, with an incidence comparable to surgical controls without heart disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjopen\/oeag053","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:19:57Z","timestamp":1774268397000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-term outcomes after septal reduction therapy for obstructive hypertrophic cardiomyopathy: a nationwide cohort study"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8049-6871","authenticated-orcid":false,"given":"Andreas","family":"Schelldorfer","sequence":"first","affiliation":[{"name":"Department of Cardiology, Cantonal Hospital Aarau , Tellstrasse 25, 5001 Aarau ,","place":["Switzerland"]},{"name":"Medical University Department, Cantonal Hospital Aarau , Tellstrasse 25, 5001 Aarau ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahel","family":"Laager","sequence":"additional","affiliation":[{"name":"Medical University Department, Cantonal Hospital Aarau , Tellstrasse 25, 5001 Aarau ,","place":["Switzerland"]},{"name":"University Hospital of Child and Adolescent Psychiatry and Psychotherapy , Bolligenstrasse 111, 3000 Bern 60 ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9830-2271","authenticated-orcid":false,"given":"Laurent M","family":"Haegeli","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cantonal Hospital Aarau , Tellstrasse 25, 5001 Aarau ,","place":["Switzerland"]},{"name":"Arrhythmia and Electrophysiology, Department of Cardiology, University Heart Center, University Hospital Zurich , R\u00e4mistrasse 100, 8091 Zurich ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Schuetz","sequence":"additional","affiliation":[{"name":"Medical University Department, Cantonal Hospital Aarau , Tellstrasse 25, 5001 Aarau ,","place":["Switzerland"]},{"name":"Medical Faculty, University of Basel , Klingelbergstrasse 61, 4056 Basel ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kutz","sequence":"additional","affiliation":[{"name":"Medical University Department, Cantonal Hospital Aarau , Tellstrasse 25, 5001 Aarau ,","place":["Switzerland"]},{"name":"Medical Faculty, University of Basel , Klingelbergstrasse 61, 4056 Basel ,","place":["Switzerland"]},{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , 1620 Tremont St, Suite 3030, Boston, MA 02120 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2981-0667","authenticated-orcid":false,"given":"H Yakup","family":"Yakupoglu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cantonal Hospital Aarau , Tellstrasse 25, 5001 Aarau ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"2026042103512322300_oeag053-B1","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"83","author":"Ommen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026042103512322300_oeag053-B2","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026042103512322300_oeag053-B3","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of hypertrophic cardiomyopathy: JACC state-of-the-art review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026042103512322300_oeag053-B4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1583\/03-1171MR.1","article-title":"Percutaneous transluminal septal artery ablation using polyvinyl alcohol foam particles for septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: acute and 3-year outcomes","volume":"11","author":"Gross","year":"2004","journal-title":"J Endovasc Ther"},{"key":"2026042103512322300_oeag053-B5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1540-8183.2010.00605.x","article-title":"Cyanoacrylate for septal ablation in hypertrophic cardiomyopathy","volume":"24","author":"Oto","year":"2011","journal-title":"J Interv Cardiol"},{"key":"2026042103512322300_oeag053-B6","first-page":"2048004016636313","article-title":"Glue septal ablation: a promising alternative to alcohol septal ablation","volume":"5","author":"Okutucu","year":"2016","journal-title":"JRSM Cardiovasc Dis"},{"key":"2026042103512322300_oeag053-B7","first-page":"350","article-title":"Microcoil embolisation for ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy","volume":"61","author":"Iacob","year":"2004","journal-title":"Kardiol Pol"},{"key":"2026042103512322300_oeag053-B8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/eurheartj\/ehm632","article-title":"Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up","volume":"29","author":"Durand","year":"2008","journal-title":"Eur Heart J"},{"key":"2026042103512322300_oeag053-B9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s12471-013-0393-z","article-title":"Microsphere embolisation as an alternative for alcohol in percutaneous transluminal septal myocardial ablation","volume":"21","author":"Vriesendorp","year":"2013","journal-title":"Neth Heart J"},{"key":"2026042103512322300_oeag053-B10","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.jcin.2016.02.026","article-title":"A simple and inexpensive option for nonsurgical septal reduction in hypertrophic obstructive cardiomyopathy: embolization of the septal artery with subcutaneous fat tissue","volume":"9","author":"\u00c7a\u011fda\u015f","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"2026042103512322300_oeag053-B11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamacardio.2022.0259","article-title":"Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy","volume":"7","author":"Zhou","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026042103512322300_oeag053-B12","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jacc.2010.07.055","article-title":"Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months\u2019 follow-up in 19 patients","volume":"57","author":"Lawrenz","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026042103512322300_oeag053-B13","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1111\/jce.15203","article-title":"Acute and chronic effects of endocardial radiofrequency ablation of septal hypertrophy in HOCM","volume":"32","author":"Lawrenz","year":"2021","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026042103512322300_oeag053-B14","first-page":"247","article-title":"Feasibility study of percutaneous transvalvular endomyocardial cryoablation for the treatment of hypertrophic obstructive cardiomyopathy","volume":"19","author":"Keane","year":"2007","journal-title":"J Invasive Cardiol"},{"key":"2026042103512322300_oeag053-B15","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jchf.2015.06.011","article-title":"A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy","volume":"3","author":"Liebregts","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2026042103512322300_oeag053-B16","doi-asserted-by":"crossref","first-page":"900469","DOI":"10.3389\/fcvm.2022.900469","article-title":"Alcohol septal ablation or septal myectomy? An updated systematic review and meta-analysis of septal reduction therapy for hypertrophic obstructive cardiomyopathy","volume":"9","author":"Zheng","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026042103512322300_oeag053-B17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jtcvs.2018.08.062","article-title":"Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a propensity score-matched cohort","volume":"157","author":"Nguyen","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026042103512322300_oeag053-B18","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.124.069378","article-title":"Long-term outcomes after septal reduction therapies in obstructive hypertrophic cardiomyopathy: insights from the SHARE registry","volume":"150","author":"Maurizi","year":"2024","journal-title":"Circulation"},{"key":"2026042103512322300_oeag053-B19","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jacc.2022.02.032","article-title":"Survival following alcohol septal ablation or septal myectomy for patients with obstructive hypertrophic cardiomyopathy","volume":"79","author":"Cui","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026042103512322300_oeag053-B20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jacc.2022.10.027","article-title":"Survival after septal reduction in patients &gt;65 years old with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Mentias","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026042103512322300_oeag053-B21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/clc.23113","article-title":"Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: systematic review and meta-analysis","volume":"42","author":"Osman","year":"2019","journal-title":"Clin Cardiol"},{"key":"2026042103512322300_oeag053-B22","doi-asserted-by":"crossref","first-page":"e028693","DOI":"10.1161\/JAHA.122.028693","article-title":"Hospital procedural volume and clinical outcomes following septal reduction therapy in obstructive hypertrophic cardiomyopathy","volume":"12","author":"Altibi","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026042103512322300_oeag053-B23","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamacardio.2016.0252","article-title":"Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003\u20132011","volume":"1","author":"Kim","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2026042103512322300_oeag053-B24","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.athoracsur.2022.05.062","article-title":"Impact of hospital volume on outcomes of septal myectomy for hypertrophic cardiomyopathy","volume":"114","author":"Holst","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"2026042103512322300_oeag053-B25","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2005.02.090","article-title":"Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy","volume":"46","author":"Ommen","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026042103512322300_oeag053-B26","doi-asserted-by":"crossref","first-page":"e007673","DOI":"10.1161\/CIRCINTERVENTIONS.118.007673","article-title":"Guideline-based referral for septal reduction therapy in obstructive hypertrophic cardiomyopathy is associated with excellent clinical outcomes","volume":"12","author":"Kimmelstiel","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"2026042103512322300_oeag053-B27","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1536\/ihj.21-095","article-title":"Effects of septal reduction therapy on acute cardiovascular events and all-cause mortality in patients with hypertrophic cardiomyopathy","volume":"62","author":"Morita","year":"2021","journal-title":"Int Heart J"},{"key":"2026042103512322300_oeag053-B28","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2026042103512322300_oeag053-B29","doi-asserted-by":"crossref","first-page":"e014986","DOI":"10.1161\/CIRCIMAGING.122.014986","article-title":"Myosin inhibition and left ventricular diastolic function in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: insights from the VALOR-HCM study","volume":"15","author":"Cremer","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026042103512322300_oeag053-B30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026042103512322300_oeag053-B31","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","article-title":"Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: outcomes through 32 weeks","volume":"147","author":"Desai","year":"2023","journal-title":"Circulation"},{"key":"2026042103512322300_oeag053-B32","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026042103512322300_oeag053-B33","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1161\/CIRCULATIONAHA.124.072445","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM","volume":"151","author":"Desai","year":"2025","journal-title":"Circulation"},{"key":"2026042103512322300_oeag053-B34","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"Elm","year":"2007","journal-title":"BMJ"},{"key":"2026042103512322300_oeag053-B35","doi-asserted-by":"crossref","first-page":"ehac544.1747","DOI":"10.1093\/eurheartj\/ehac544.1747","article-title":"Population estimates of obstructive and non-obstructive hypertrophic cardiomyopathy in the UK and Germany","volume":"43","author":"Schultze","year":"2022","journal-title":"Eur Heart J"},{"key":"2026042103512322300_oeag053-B36","doi-asserted-by":"crossref","first-page":"e012832","DOI":"10.1136\/bmjopen-2016-012832","article-title":"Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study","volume":"6","author":"Sundb\u00f8ll","year":"2016","journal-title":"BMJ Open"},{"key":"2026042103512322300_oeag053-B37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/CLEP.S139300","article-title":"Misclassification of hypertrophic cardiomyopathy: validation of diagnostic codes","volume":"9","author":"Magnusson","year":"2017","journal-title":"Clin Epidemiol"},{"key":"2026042103512322300_oeag053-B38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/pds.3263","article-title":"One-to-many propensity score matching in cohort studies","volume":"21","author":"Rassen","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026042103512322300_oeag053-B39","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/aje\/kwt212","article-title":"Selecting an appropriate caliper can be essential for achieving good balance with propensity score matching","volume":"179","author":"Lunt","year":"2014","journal-title":"Am J Epidemiol"},{"key":"2026042103512322300_oeag053-B40","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary Variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"key":"2026042103512322300_oeag053-B41","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"2026042103512322300_oeag053-B42","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1161\/CIRCULATIONAHA.122.063383","article-title":"Can novel myosin inhibitors defer septal reduction therapy in HCM? At what risk and at what cost?","volume":"147","author":"Rakowski","year":"2023","journal-title":"Circulation"},{"key":"2026042103512322300_oeag053-B43","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1016\/j.jacc.2018.09.064","article-title":"Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy","volume":"72","author":"Batzner","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026042103512322300_oeag053-B44","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/eurheartj\/ehx819","article-title":"The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies","volume":"39","author":"Charron","year":"2018","journal-title":"Eur Heart J"},{"key":"2026042103512322300_oeag053-B45","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.amjcard.2023.07.150","article-title":"Surgical outcomes of septal myectomy with and without mitral valve surgeries in hypertrophic cardiomyopathy: a national propensity-matched analysis (2005 to 2020)","volume":"205","author":"Faisaluddin","year":"2023","journal-title":"Am J Cardiol"},{"key":"2026042103512322300_oeag053-B46","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jchf.2014.06.012","article-title":"Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy","volume":"2","author":"Vriesendorp","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026042103512322300_oeag053-B47","doi-asserted-by":"crossref","first-page":"353","DOI":"10.21037\/acs.2017.07.07","article-title":"Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience","volume":"6","author":"Rastegar","year":"2017","journal-title":"Ann Cardiothorac Surg"},{"key":"2026042103512322300_oeag053-B48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.amjmed.2016.09.015","article-title":"Nonobstructive hypertrophic cardiomyopathy out of the shadows: known from the beginning but largely ignored \u2026 until now","volume":"130","author":"Maron","year":"2017","journal-title":"Am J Med"},{"key":"2026042103512322300_oeag053-B49","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.01.023","article-title":"Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy","volume":"67","author":"Maron","year":"2016","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjopen\/advance-article-pdf\/doi\/10.1093\/ehjopen\/oeag053\/67511009\/oeag053.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/6\/2\/oeag053\/67511009\/oeag053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/6\/2\/oeag053\/67511009\/oeag053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:51:34Z","timestamp":1776757894000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjopen\/article\/doi\/10.1093\/ehjopen\/oeag053\/8540498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjopen\/oeag053","relation":{},"ISSN":["2752-4191"],"issn-type":[{"value":"2752-4191","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]},"article-number":"oeag053"}}